AU2008277350B2 - Preprocalcitonin antigen T epitopes - Google Patents

Preprocalcitonin antigen T epitopes Download PDF

Info

Publication number
AU2008277350B2
AU2008277350B2 AU2008277350A AU2008277350A AU2008277350B2 AU 2008277350 B2 AU2008277350 B2 AU 2008277350B2 AU 2008277350 A AU2008277350 A AU 2008277350A AU 2008277350 A AU2008277350 A AU 2008277350A AU 2008277350 B2 AU2008277350 B2 AU 2008277350B2
Authority
AU
Australia
Prior art keywords
peptide
seq
cells
composition
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008277350A
Other languages
English (en)
Other versions
AU2008277350A1 (en
Inventor
Pierre G. Coulie
Faten El Hage
Fathia Mami-Chouaib
Vincent Stroobant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Gustave Roussy (IGR)
Publication of AU2008277350A1 publication Critical patent/AU2008277350A1/en
Application granted granted Critical
Publication of AU2008277350B2 publication Critical patent/AU2008277350B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008277350A 2007-06-22 2008-06-19 Preprocalcitonin antigen T epitopes Ceased AU2008277350B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290777A EP2006384A1 (en) 2007-06-22 2007-06-22 Preprocalcitonin-derived antigen epitopes
EP07290777.7 2007-06-22
PCT/IB2008/002625 WO2009010874A2 (en) 2007-06-22 2008-06-19 Preprocalcitonin antigen t epitopes

Publications (2)

Publication Number Publication Date
AU2008277350A1 AU2008277350A1 (en) 2009-01-22
AU2008277350B2 true AU2008277350B2 (en) 2013-08-22

Family

ID=38676532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008277350A Ceased AU2008277350B2 (en) 2007-06-22 2008-06-19 Preprocalcitonin antigen T epitopes

Country Status (10)

Country Link
US (1) US8492342B2 (https=)
EP (2) EP2006384A1 (https=)
JP (1) JP5393661B2 (https=)
CN (1) CN101730711B (https=)
AT (1) ATE539087T1 (https=)
AU (1) AU2008277350B2 (https=)
CA (1) CA2691406C (https=)
DK (1) DK2170941T3 (https=)
ES (1) ES2379209T3 (https=)
WO (1) WO2009010874A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3115058A1 (fr) * 2015-07-09 2017-01-11 Institut Gustave Roussy Peptides immunogenes de preprocalcitonine
CN106110305B (zh) * 2016-08-03 2018-07-17 黑龙江中医药大学 包含升麻皂苷的药物制剂及其应用
CN105999232B (zh) * 2016-08-03 2018-07-03 黑龙江中医药大学 包含升麻皂苷的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075179A2 (en) * 2000-03-31 2001-10-11 Ludwig Institute For Cancer Research Preprocalcitonin as tumor rejection antigen precursor and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075179A2 (en) * 2000-03-31 2001-10-11 Ludwig Institute For Cancer Research Preprocalcitonin as tumor rejection antigen precursor and uses thereof

Also Published As

Publication number Publication date
ES2379209T3 (es) 2012-04-23
CN101730711A (zh) 2010-06-09
WO2009010874A2 (en) 2009-01-22
ATE539087T1 (de) 2012-01-15
WO2009010874A3 (en) 2009-03-26
US8492342B2 (en) 2013-07-23
AU2008277350A1 (en) 2009-01-22
US20100184700A1 (en) 2010-07-22
CN101730711B (zh) 2013-05-01
EP2170941B1 (en) 2011-12-28
CA2691406C (en) 2015-11-24
DK2170941T3 (da) 2012-04-16
EP2170941A2 (en) 2010-04-07
JP2010530748A (ja) 2010-09-16
EP2006384A1 (en) 2008-12-24
JP5393661B2 (ja) 2014-01-22
CA2691406A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
US20230277641A1 (en) Telomerase polypeptide vaccine for treating cancer
AU749544B2 (en) Tumor antigen peptides originating in cyclophilin B
AU762903B2 (en) Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
WO2021074655A1 (en) Cancer vaccine
AU2008277350B2 (en) Preprocalcitonin antigen T epitopes
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
US7071294B1 (en) Tumor antigen protein art-1 and tumor antigen peptide thereof
AU2016289727B2 (en) Immunogenic preprocalcitonin peptides
EP1373505A2 (en) Tri-hybrid melanoma antigen
HK1177762A (en) Polypeptides
HK1177762B (en) Polypeptides
AU2002244196A1 (en) Tri-hybrid melanoma antigen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired